重组人碱性成纤维细胞生长因子联合封闭负压引流技术对创面修复的疗效及瘢痕形成的影响

Effects of combining recombinant human basic fibroblast growth factor with vacuum sealing drainage on wound repair and scar formation

目的分析重组人碱性成纤维细胞生长因子(rh-bFGF)联合封闭负压引流技术(VSD)对创面修复治疗的疗效及瘢痕形成的影响。方法选取2021年4月至2024年2月山西省太原市中心医院整形外科进行创面修复治疗的104例患者,根据随机数字表法分为观察组(n=52)和对照组(n=52)。对照组予VSD治疗,观察组予rh-bFGF联合VSD治疗。观察记录2组临床疗效、创面愈合时间、总换药次数、引流管更换数、住院时间、治疗后14 d创面愈合率及不良反应发生率,比较2组治疗前及治疗后14 d血清肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)水平,比较2组治疗结束后3个月温哥华瘢痕评定量表(VSS)评分。结果观察组有效率为96·15%(50/52),对照组为80·77%(42/52),治疗组明显高于对照组(P<0·05)。观察组创面愈合时间、总换药次数、引流管更换数、住院时间均少于对照组(均P<0·05),治疗后14 d创面愈合率高于对照组(P<0·05)。治疗结束后3个月,观察组VSS评分明显低于对照组(P<0·05)。治疗后14 d,2组血清TNF-α、CRP水平均降低(均P<0·05),且观察组均低于对照组(均P<0·05)。观察组不良反应发生率为7·69%(4/52),对照组不良反应发生率为15·38%(8/52),2组不良反应发生率比较差异无统计学意义(P>0·05)。结论rh-bFGF联合VSD技术在创面修复治疗中疗效显著,不仅能有效缩短创面愈合时间、住院时间,提高创面愈合率,同时能抑制炎症反应,减少瘢痕形成。

Objective To explore the effecst of recombinant human basic fibroblast growth factor(rh-b FGF) combined with vacuum sealing drainage(VSD) on wound repair and scar formation. Methods A total of 104 cases who underwent wound repair from April 2021 to February 2024 were divided into experiment group(n=52) and control group(n=52) according to random number method. The control group was treated with VSD, and the experiment group was treated with rh-b FGF in combination with VSD. The clinical efficacy, wound healing time, total number of dressing changes, number of drain replacements, length of hospital stay, wound healing rate at 14 days post-treatment, and the incidence of adverse reactions were observed and recorded for both groups.Additionally, serum levels of tumor necrosis factor-alpha(TNF-α) and C-reactive protein(CRP) were compared between the two groups before treatment and 14 days after treatment. Furthermore, the vancouver scar scale(VSS) scores were evaluated for both groups three months following the completion of treatment. Results The experimental group demonstrated an effectiveness rate of 96·15%(50/52), significantly higher than the control group's rate of 80·77%(42/52)(P<0.05). Additionally, the experimental group had significantly shorter wound healing time, fewer dressing changes, fewer drain replacements, and a shorter length of hospital stay compared to the control group(all P<0·05). At 14 days post-treatment, the wound healing rate in the experimental group was also notably higher than that in the control group(P<0·05).Three months after treatment, the Vancouver Scar Scale(VSS) score in the experimental group was significantly lower than that in the control group(P<0.05). At 14 days post-treatment,serum levels of TNF-α and CRP decreased in both groups(all P<0.05), with the experimental group showing significantly lower levels than the control group(all P<0·05). The incidence of adverse reactions was 7·69%(4/52) in the experimental group and 15·38%(8/52) in the control group, with no significant difference between the two groups(P>0·05). Conclusion The combination of rhb FGF and VSD technology exerts a significant effect on woundrepair treatment, effectively reducing both the duration of wound healing and hospitalization while enhancing the wound healing rate, minimizing scar formation, and mitigating inflammation.